{'fraction_non_alphanumeric': 0.0394121576486306, 'fraction_numerical': 0.009352037408149633, 'mean_word_length': 4.8515625, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Influence of hormone replacement therapy (oral and transdermal) on activity of erythrocyte Zn/Cu superoxide dismutase (Zn/Cu-SOD) in postmenopausal women].

OBJECTIVE
The aim of the study was to determine the effect of hormone replacement therapy (oral and transdermal) on the erythrocyte antioxidant enzyme activity in postmenopausal women.


DESIGN
Prospective clinical study.


MATERIAL AND METHODS
The erythrocyte Cu/Zn superoxide dismutase activity was measured in 14 postmenopausal women (the mean age 58.5 +/- 5.1 years) who received either oral (7) or transdermal (7) HRT. Additionally the activity of the enzyme was compared between the subgroup of healthy women and those with coronary heart disease (CHD). The measurements was made by the use of commercial kit (Bioxytech SOD-525 TM Assay).


RESULTS
There were no differences statistically significant between erythrocyte Cu/Zn-SOD activity before and after 3 months of HRT in all patients. However, lower activity of erythrocyte Cu/Zn-SOD was observed in the subgroup of women who were suffering from (CHD) in comparison to their healthy volunteers. The way of HRT administration also influenced erythrocyte Cu/Zn-SOD activity. The erythrocyte Cu/Zn-SOD activity after 3 months of treatment was slightly higher in group who received oral HRT.


CONCLUSIONS
HRT (oral and transdermal) leads to changes in erythrocyte Cu/Zn-SOD activity. The presence of (CHD) postmenopausal women seems to influence the erythrocyte Cu/Zn-SOD activity.